Goldman Sachs raised the firm’s price target on Crinetics (CRNX) to $45 from $40 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharma’s Positive Earnings Call Highlights PALSONIFY Success
- Crinetics Pharmaceuticals: Strong Market Entry and Financial Position Support Buy Rating
- Crinetics price target lowered to $108 from $143 at Citizens JMP
- Crinetics Pharmaceuticals Reports Positive Launch and Financials
- Crinetics reports Q3 EPS ($1.38), consensus ($1.25)